{
    "id": 15094,
    "fullName": "RUNX1 - RUNX1T1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RUNX1-RUNX1T1 (also referred to as RUNX1-ETO) results from the fusion of RUNX1 and RUNX1T1, and leads to altered transcriptional regulation and a mutator phenotype (PMID: 22201794, PMID: 26050648). RUNX1-RUNX1T1 fusions are associated with acute myeloid leukemia (PMID: 22201794).",
            "references": [
                {
                    "id": 4077,
                    "pubMedId": 22201794,
                    "title": "RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22201794"
                },
                {
                    "id": 4078,
                    "pubMedId": 26050648,
                    "title": "The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26050648"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 861,
        "geneSymbol": "RUNX1",
        "terms": [
            "RUNX1",
            "AML1",
            "AML1-EVI-1",
            "AMLCR1",
            "CBF2alpha",
            "CBFA2",
            "EVI-1",
            "PEBP2aB",
            "PEBP2alpha"
        ]
    },
    "variant": "RUNX1 - RUNX1T1",
    "createDate": "12/09/2015",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 862,
                "geneSymbol": "RUNX1T1",
                "terms": [
                    "RUNX1T1",
                    "AML1-MTG8",
                    "AML1T1",
                    "CBFA2T1",
                    "CDR",
                    "ETO",
                    "MTG8",
                    "ZMYND2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 3777,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of I-CBP112 and JQ1 worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)",
            "molecularProfile": {
                "id": 15350,
                "profileName": "RUNX1 - RUNX1T1"
            },
            "therapy": {
                "id": 3298,
                "therapyName": "I-CBP112 + JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4120,
                    "pubMedId": 26552700,
                    "title": "Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26552700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3778,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of I-CBP112 and Doxorubicin worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)",
            "molecularProfile": {
                "id": 15350,
                "profileName": "RUNX1 - RUNX1T1"
            },
            "therapy": {
                "id": 3299,
                "therapyName": "Doxorubicin + I-CBP112",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4120,
                    "pubMedId": 26552700,
                    "title": "Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26552700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10464,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture (PMID: 26837761).",
            "molecularProfile": {
                "id": 15350,
                "profileName": "RUNX1 - RUNX1T1"
            },
            "therapy": {
                "id": 5507,
                "therapyName": "GSK690",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8467,
                    "pubMedId": 26837761,
                    "title": "Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26837761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10463,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RN-1 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture, and inhibited tumor growth in xenograft models (PMID: 26837761).",
            "molecularProfile": {
                "id": 15350,
                "profileName": "RUNX1 - RUNX1T1"
            },
            "therapy": {
                "id": 5506,
                "therapyName": "RN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8467,
                    "pubMedId": 26837761,
                    "title": "Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26837761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3774,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, I-CBP112 inhibited clonogenic growth in a leukemia cell line harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700).",
            "molecularProfile": {
                "id": 15350,
                "profileName": "RUNX1 - RUNX1T1"
            },
            "therapy": {
                "id": 3297,
                "therapyName": "I-CBP112",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4120,
                    "pubMedId": 26552700,
                    "title": "Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26552700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18054,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "RUNX1-RUNX1T1 fusions (t(8;21)(q22;q22.1)) are associated with a favorable prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 15350,
                "profileName": "RUNX1 - RUNX1T1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6079,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical analyses, the t(8;21) cytogenetic abnormality, which leads to the RUNX1-RUNX1T1 fusion, is associated with core-binding factor acute myeloid leukemia and favorable prognosis (PMID: 22180162, PMID: 9746770, PMID: 25111512).",
            "molecularProfile": {
                "id": 15350,
                "profileName": "RUNX1 - RUNX1T1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5287,
                    "pubMedId": 22180162,
                    "title": "Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22180162"
                },
                {
                    "id": 5288,
                    "pubMedId": 9746770,
                    "title": "The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9746770"
                },
                {
                    "id": 5289,
                    "pubMedId": 25111512,
                    "title": "Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25111512"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6080,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).",
            "molecularProfile": {
                "id": 22438,
                "profileName": "RUNX1 - RUNX1T1 KIT mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1127,
                    "pubMedId": 18648004,
                    "title": "Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18648004"
                },
                {
                    "id": 5289,
                    "pubMedId": 25111512,
                    "title": "Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25111512"
                },
                {
                    "id": 5290,
                    "pubMedId": 16384925,
                    "title": "Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16384925"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18022,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32936,
                "profileName": "RUNX1 - RUNX1T1 KIT N822K"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18025,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) demonstrated reduced ability to inhibit Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture compared to other kinase inhibitors (PMID: 31309543).",
            "molecularProfile": {
                "id": 32936,
                "profileName": "RUNX1 - RUNX1T1 KIT N822K"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18023,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32936,
                "profileName": "RUNX1 - RUNX1T1 KIT N822K"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18024,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) demonstrated reduced ability to inhibit Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture compared to other kinase inhibitors (PMID: 31309543).",
            "molecularProfile": {
                "id": 32936,
                "profileName": "RUNX1 - RUNX1T1 KIT N822K"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18021,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32936,
                "profileName": "RUNX1 - RUNX1T1 KIT N822K"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18020,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32936,
                "profileName": "RUNX1 - RUNX1T1 KIT N822K"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15350,
            "profileName": "RUNX1 - RUNX1T1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22438,
            "profileName": "RUNX1 - RUNX1T1 KIT mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32936,
            "profileName": "RUNX1 - RUNX1T1 KIT N822K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}